Search Result

Results for "

triglyceride synthesis

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Acetyl-CoA Carboxylase (2) Acyltransferase (4) ANGPTL (2) Apolipoprotein (3) Biochemical Assay Reagents (3) Endogenous Metabolite (2) Environmental Pollutants (1) FABP (1) Farnesyl Transferase (1) Fatty Acid Synthase (FASN) (2) Ferroptosis (3) Fungal (2) FXR (2) Glutathione Peroxidase (3) Isotope-Labeled Compounds (1) LDLR (3) LXR (1) MicroRNA (2) Mitochondrial Metabolism (2) PPAR (1) Reactive Oxygen Species (ROS) (3) Reference Standards (4)
By Research Areas:	Cardiovascular Disease (6) Endocrinology (1) Infection (2) Inflammation/Immunology (4) Metabolic Disease (19)
Oligonucleotides:	Antisense Oligonucleotides (4)

Inhibitors & Agonists

Screening Libraries

Natural
Products

Isotope-Labeled Compounds

Oligonucleotides

Targets Recommended: DNA/RNA Synthesis Microsomal Triglyceride Transfer Protein (MTP) ATGL

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-129098

DMHCA 1 Publications Verification	LXR	Metabolic Disease
DMHCA, a potent and selective LXR agonist, specifically activates the cholesterol efflux arm of the LXR pathway without stimulating triglyceride synthesis. DMHCA has anti-inflammatory effects?and can be used for the research of cholesterol homeostasis diabetes .

HY-B2004

Thifluzamide	Environmental Pollutants Fungal Mitochondrial Metabolism	Infection
Thifluzamide is a fungicide that inhibits fungal respiration by blocking the ubiquinone-binding site in mitochondrial complex II. Thifluzamide exhibits significant activity against Basidiomycota pathogens (such as Rhizoctonia cerealis, Ustilago and Puccinia genera) and is commonly used in studies on wheat sharp eyespot. Thifluzamide displays a dual mechanism in regulating lipid metabolism: it reduces fatty acid synthase activity to inhibit endogenous fatty acid synthesis, and increases carnitine palmitoyltransferase-I activity to accelerate fatty acid β-oxidation, thereby reducing total cholesterol and triglyceride levels in the liver. Thifluzamide also induces hepatotoxicity in zebrafish models and carries a risk of developmental toxicity. Thifluzamide inhibition of Rhizoctonia cerealis may result in low to moderate levels of drug resistance, leading to the generation of stable drug-resistant mutants .

HY-N0468

Rebaudioside D 1 Publications Verification	FXR Acetyl-CoA Carboxylase	Metabolic Disease
Rebaudioside D is an orally active sweetener that targets and activates FXR, modulates Acetyl-CoA Carboxylase, and inhibits 3-hydroxy-3-methylglutaryl-CoA reductase. Rebaudioside D regulates bile acid homeostasis and lipid metabolism, reduces the synthesis rates of fatty acids and cholesterol, and exerts multiple effects including anti-adipogenesis, hepatoprotection, anti-steatosis, gut microbiota modulation, enhancement of secondary bile acid metabolism, anti-endotoxin activity, regulation of bile acid transport, and inhibition of bile acid efflux. Rebaudioside D also reduces body weight gain, visceral fat accumulation, hepatic triglyceride and cholesterol accumulation, hepatic lipid peroxidation, and decreases the circulating level of lipopolysaccharide-binding protein. Rebaudioside D additionally enhances the secondary bile acid metabolic pathway of intestinal bacteria, upregulates the gene expression of ileal organic solute transporter α, and downregulates the gene expression of hepatic bile salt export pump. Rebaudioside D does not affect glucose homeostasis, alter total caloric intake or fecal energy excretion, induce weight gain, exacerbate obesity, promote hepatic steatosis, impair brown adipose tissue function, nor change skeletal muscle metabolism-related proteins. Rebaudioside D can be used in diet-induced obesity and obesity-related research .

HY-W015600

2-Acetamidophenol Orthocetamol	Ferroptosis Glutathione Peroxidase Reactive Oxygen Species (ROS) LDLR	Cardiovascular Disease Inflammation/Immunology
2-Acetamidophenol (Orthocetamol) is a regulator that targets ferroptosis and glutathione metabolic pathways, is the ortho-regioisomer of Paracetamol (HY-66005). 2-Acetamidophenol has anti-atherosclerotic activity, and inhibiting total cholesterol (TC) and triglyceride (TG) in a zebrafish hyperlipidemia model with IC₅₀s for 30 μM and 40 μM, respectively. 2-Acetamidophenol upregulates the expression of glutathione synthesis-related genes (such as GCLC, GCLM, GSS) and iron ion transport genes (such as FPN1, FTH), reduces the accumulation of intracellular reactive oxygen species (ROS) and ferrous ions (Fe ²⁺), and enhances the activity of glutathione peroxidase GPX4, thereby inhibiting macrophage phagocytosis of oxidized low-density lipoprotein (ox-LDL) and foam cell formation .

HY-N0686

Pseudoprotodioscin 1 Publications Verification	Fatty Acid Synthase (FASN) MicroRNA	Metabolic Disease
Pseudoprotodioscin, a furostanoside, inhibits SREBP1/2 and microRNA 33a/b levels and reduces the gene expression regarding the synthesis of cholesterol and triglycerides .

HY-12425

DGAT1-IN-1 2 Publications Verification	Acyltransferase	Metabolic Disease
DGAT1-IN-1 is a diacylglycerol O-acyltransferase 1 (DGAT1) inhibitor with a human IC₅₀ of <10 nM and a mouse IC₅₀ of <50 nM. DGAT1-IN-1 is applicable to the research of obesity-related diseases, type 2 diabetes and diabetes-related diseases .

HY-153491

Olezarsen ISIS 678354; IONIS-APOCIII-LRx; AKCEA-APOCIII-LRx	Apolipoprotein	Cardiovascular Disease
Olezarsen (ISIS 678354;IONIS-APOCIII-LRx) is a GalNAc-modified antisense oligonucleotide. Olezarsen binds to APOC3 mRNA and induces its degradation via ribonuclease H1-mediated sense strand cleavage, thereby reducing hepatic apolipoprotein C-III (apoC-III) synthesis. Olezarsen reduces plasma triglyceride, apolipoprotein B and non-high-density lipoprotein cholesterol levels. Olezarsen is applicable to research related to familial chylomicronemia syndrome, hypertriglyceridemia and atherosclerotic cardiovascular disease .

HY-156259

PF-07202954	Acyltransferase	Inflammation/Immunology
PF-07202954 is an orally active, highly selective DGAT2 inhibitor with an IC₅₀ of 10 nM against human DGAT2 and an IC₅₀ of 17 nM against rat DGAT2. PF-07202954 reduces triglyceride synthesis, decreases hepatic triglyceride content and plasma triglyceride levels, inhibits de novo lipogenesis, and suppresses the hepatic SREBP signaling pathway as well as the expression of SREBP target genes. PF-07202954 is applicable to research related to non-alcoholic steatohepatitis .

HY-153491A

Olezarsen sodium ISIS 678354 sodium; IONIS-APOCIII-LRx sodium; AKCEA-APOCIII-LRx sodium	Apolipoprotein	Cardiovascular Disease
Olezarsen (ISIS 678354;IONIS-APOCIII-LRx) sodium is a GalNAc-modified antisense oligonucleotide. Olezarsen sodium binds to APOC3 mRNA and induces its degradation via ribonuclease H1-mediated sense strand cleavage, thereby reducing hepatic apolipoprotein C-III (apoC-III) synthesis. Olezarsen sodium reduces plasma triglyceride, apolipoprotein B and non-high-density lipoprotein cholesterol levels. Olezarsen sodium is applicable to research related to familial chylomicronemia syndrome, hypertriglyceridemia and atherosclerotic cardiovascular disease .

HY-110381

JNJ-DGAT2-A	Acyltransferase	Metabolic Disease
JNJ-DGAT2-A is a selective diacylglycerol acyltransferase 2 (DGAT2) inhibitor with an IC₅₀ value of 0.14 μM in human DGAT2-expressing Sf9 insect cell membranes. JNJ-DGAT2-A can be used for the research of triglyceride (TG) synthesis .

HY-N14035

Garcinia cambogia extract	FABP PPAR	Metabolic Disease
Garcinia cambogia extract is an orally active anti-obesity agent . Garcinia cambogia extract upregulates the gene expression of aP2, SREBP1c, PPARγ2 and C/EBPα. Garcinia cambogia extract reduces the rate of body weight gain, visceral fat accumulation, lipid levels in blood and liver, as well as plasma insulin and leptin levels . Garcinia cambogia extract ameliorates high-fat diet-induced obesity .

HY-153497A

Vupanorsen sodium IONIS ANGPT-L3Rx sodium; ISIS 703802 sodium	ANGPTL	Metabolic Disease
Vupanorsen (sodium) is an N-acetyl galactosamine-conjugated antisense oligonucleotide that inhibits Angiopoietin-like 3 (ANGPTL3) protein synthesis. Vupanorsen (sodium) lowers triglycerides and atherogenic lipoproteins.

HY-W015600R

2-Acetamidophenol (Standard) Orthocetamol (Standard)	Reference Standards Ferroptosis Glutathione Peroxidase Reactive Oxygen Species (ROS) LDLR	Cardiovascular Disease Inflammation/Immunology
2-Acetamidophenol (Standard) is the analytical standard of 2-Acetamidophenol. This product is intended for research and analytical applications. 2-Acetamidophenol (Orthocetamol) is a regulator that targets ferroptosis and glutathione metabolic pathways, is the ortho-regioisomer of Paracetamol (HY-66005). 2-Acetamidophenol has anti-atherosclerotic activity, and inhibiting total cholesterol (TC) and triglyceride (TG) in a zebrafish hyperlipidemia model with IC₅₀s for 30 μM and 40 μM, respectively. 2-Acetamidophenol upregulates the expression of glutathione synthesis-related genes (such as GCLC, GCLM, GSS) and iron ion transport genes (such as FPN1, FTH), reduces the accumulation of intracellular reactive oxygen species (ROS) and ferrous ions (Fe ²⁺), and enhances the activity of glutathione peroxidase GPX4, thereby inhibiting macrophage phagocytosis of oxidized low-density lipoprotein (ox-LDL) and foam cell formation .

HY-W015600S

2-Acetamidophenol-d3 Orthocetamol-d₃	Isotope-Labeled Compounds Ferroptosis Glutathione Peroxidase Reactive Oxygen Species (ROS) LDLR	Cardiovascular Disease Inflammation/Immunology
2-Acetamidophenol-d₃ (Orthocetamol-d₃) is the deuterium labeled 2-Acetamidophenol (HY-W015600). 2-Acetamidophenol (Orthocetamol) is a regulator that targets ferroptosis and glutathione metabolic pathways, is the ortho-regioisomer of Paracetamol (HY-66005). 2-Acetamidophenol has anti-atherosclerotic activity, and inhibiting total cholesterol (TC) and triglyceride (TG) in a zebrafish hyperlipidemia model with IC50s for 30 μM and 40 μM, respectively. 2-Acetamidophenol upregulates the expression of glutathione synthesis-related genes (such as GCLC, GCLM, GSS) and iron ion transport genes (such as FPN1, FTH), reduces the accumulation of intracellular reactive oxygen species (ROS) and ferrous ions (Fe2+), and enhances the activity of glutathione peroxidase GPX4, thereby inhibiting macrophage phagocytosis of oxidized low-density lipoprotein (ox-LDL) and foam cell formation .

HY-153497

Vupanorsen IONIS ANGPT-L3Rx; ISIS 703802	ANGPTL	Metabolic Disease
Vupanorsen is an N-acetyl galactosamine-conjugated antisense oligonucleotide that inhibits Angiopoietin-like 3 (ANGPTL3) protein synthesis. Vupanorsen lowers triglycerides and atherogenic lipoproteins.

HY-127055

Tiadenol	Apolipoprotein	Metabolic Disease Endocrinology
Tiadenol is an absorbable hypolipidemic agent. Tiadenol can effectively reduce *triglycerides* and decrease the level of apolipoprotein E in very low-density lipoproteins in hyperlipoproteinemia. Tiadenol causes hepatomegaly in rats and affects their hepatic lipid levels, cholesterol synthesis and absorption at high doses. Tiadenol can be used in the research of endocrine and metabolic diseases such as hyperlipidemia .

HY-N0468R

Rebaudioside D (Standard)	Reference Standards Acetyl-CoA Carboxylase FXR	Metabolic Disease
Rebaudioside D (Standard) is the analytical standard of Rebaudioside D. This product is intended for research and analytical applications. Rebaudioside D is an orally active sweetener that targets and activates FXR, modulates Acetyl-CoA Carboxylase, and inhibits 3-hydroxy-3-methylglutaryl-CoA reductase. Rebaudioside D regulates bile acid homeostasis and lipid metabolism, reduces the synthesis rates of fatty acids and cholesterol, and exerts multiple effects including anti-adipogenesis, hepatoprotection, anti-steatosis, gut microbiota modulation, enhancement of secondary bile acid metabolism, anti-endotoxin activity, regulation of bile acid transport, and inhibition of bile acid efflux. Rebaudioside D also reduces body weight gain, visceral fat accumulation, hepatic triglyceride and cholesterol accumulation, hepatic lipid peroxidation, and decreases the circulating level of lipopolysaccharide-binding protein. Rebaudioside D additionally enhances the secondary bile acid metabolic pathway of intestinal bacteria, upregulates the gene expression of ileal organic solute transporter α, and downregulates the gene expression of hepatic bile salt export pump. Rebaudioside D does not affect glucose homeostasis, alter total caloric intake or fecal energy excretion, induce weight gain, exacerbate obesity, promote hepatic steatosis, impair brown adipose tissue function, nor change skeletal muscle metabolism-related proteins. Rebaudioside D can be used in diet-induced obesity and obesity-related research .

HY-N9535

tert-OMe-byakangelicin	Others	Metabolic Disease
tert-OMe-byakangelicin is a coumarin that can enhances the adrenaline-induced lipolytic effect and inhibits insulin-stimulated triglyceride synthesis from glucose in fat cells .

HY-N0686R

Pseudoprotodioscin (Standard)	Reference Standards Fatty Acid Synthase (FASN) MicroRNA	Metabolic Disease
Pseudoprotodioscin (Standard) is the analytical standard of Pseudoprotodioscin. This product is intended for research and analytical applications. Pseudoprotodioscin, a furostanoside, inhibits SREBP1/2 and microRNA 33a/b levels and reduces the gene expression regarding the synthesis of cholesterol and triglycerides .

HY-163452

Squalene synthase-IN-2	Farnesyl Transferase	Metabolic Disease
Squalene synthase-IN-2 (comppund isomer A-(1S, 3R)-14i) is an orally active squalene synthase inhibitor with IC₅₀ values of 3.4, 99 nM for squalene synthase and cholesterol synthesis, respectively. Squalene synthase-IN-2 reduces plasma cholesterol and triglyceride .

HY-B2004R

Thifluzamide (Standard)	Reference Standards Fungal Mitochondrial Metabolism	Infection
Thifluzamide (Standard) is the analytical standard of Thifluzamide. This product is intended for research and analytical applications. Thifluzamide is a fungicide that inhibits fungal respiration by blocking the ubiquinone-binding site in mitochondrial complex II. Thifluzamide exhibits significant activity against Basidiomycota pathogens (such as Rhizoctonia cerealis, Ustilago and Puccinia genera) and is commonly used in studies on wheat sharp eyespot. Thifluzamide displays a dual mechanism in regulating lipid metabolism: it reduces fatty acid synthase activity to inhibit endogenous fatty acid synthesis, and increases carnitine palmitoyltransferase-I activity to accelerate fatty acid β-oxidation, thereby reducing total cholesterol and triglyceride levels in the liver. Thifluzamide also induces hepatotoxicity in zebrafish models and carries a risk of developmental toxicity. Thifluzamide inhibition of Rhizoctonia cerealis may result in low to moderate levels of drug resistance, leading to the generation of stable drug-resistant mutants .

HY-E70936A

Glycerokinase, Bacillus stearothermophilus	Biochemical Assay Reagents	Metabolic Disease
Glycerokinase, Bacillus stearothermophilus (EC 2.7.1.30) is a phosphotransferase enzyme involved in triglycerides and glycerophospholipids synthesis. Glycerokinase catalyzes tge MgATP-dependent phosphorylation of glycerol to produce sn-glycerol-3-phosphate and is the rate limiting enzyme in the utilization of glycerol.

HY-E70936B

Glycerokinase, Cellulomonas sp.	Biochemical Assay Reagents	Metabolic Disease
Glycerokinase, Cellulomonas sp. (EC 2.7.1.30) is a phosphotransferase enzyme involved in triglycerides and glycerophospholipids synthesis. Glycerokinase catalyzes tge MgATP-dependent phosphorylation of glycerol to produce sn-glycerol-3-phosphate and is the rate limiting enzyme in the utilization of glycerol.

HY-E70936C

Glycerokinase, Escherichia coli	Biochemical Assay Reagents	Metabolic Disease
Glycerokinase, Escherichia coli (EC 2.7.1.30) is a phosphotransferase enzyme involved in triglycerides and glycerophospholipids synthesis. Glycerokinase catalyzes tge MgATP-dependent phosphorylation of glycerol to produce sn-glycerol-3-phosphate and is the rate limiting enzyme in the utilization of glycerol.

HY-E70936

Glycerokinase, Streptomyces canus	Endogenous Metabolite	Metabolic Disease
Glycerokinase, Streptomyces canus (EC 2.7.1.30) is a phosphotransferase enzyme involved in triglycerides and glycerophospholipids synthesis. Glycerol kinase catalyzes tge MgATP-dependent phosphorylation of glycerol to produce sn-glycerol-3-phosphate and is the rate limiting enzyme in the utilization of glycerol.

HY-153507

DGAT1-IN-4	Acyltransferase	Metabolic Disease
DGAT1-IN-4 is a potent, orally active, and selective DGAT1 inhibitor with an IC₅₀ of 17 nM. DGAT1-IN-4 exhibits >588-fold selectivity over DGAT2. DGAT1-IN-4 suppresses intracellular triglyceride synthesis in mouse myoblast cells. DGAT1-IN-4 suppresses body weight gain in diet-induced obese dogs. DGAT1-IN-4 can be used for the research of obesity .

HY-130064

Omega-3 acid ethyl esters P-OM3	Endogenous Metabolite	Cardiovascular Disease Metabolic Disease
Omega-3 acid ethyl esters (P-OM3) is a omega-3 polyunsaturated fatty acid. Omega-3 acid ethyl esters can be used for the researches of severe hypertriglyceridemia and cardiovascular diseases .

Cat. No.	Product Name

HY-L182

Fatty Acids Compound Library	285 compounds
Fatty acids (FAs) are the main components of lipids. The synthesis of fatty acids mainly involves the Triglyceride (TG) cycle and De Novo Lipogenesis (DNL). Fatty acids which exist widely in organisms are components of cell membranes and play an indispensable role in cell signaling. In addition, FFAs can be taken up from circulating plasma by all mitochondria-containing cells, and they are metabolized by β-oxidation and the citric acid cycle to release large amounts of energy in the form of ATP. Abnormal fatty acid metabolism is associated with the occurrence and development of cardiovascular diseases, diabetes, fatty liver, hyperthyroidism, and other diseases. MCE offers a unique collection of fatty acid compounds. Fatty Acids Compound Library is an important tool for the study of energy metabolism and drug development of metabolism-related diseases.

Fatty Acids Compound Library

285 compounds

Fatty acids (FAs) are the main components of lipids. The synthesis of fatty acids mainly involves the Triglyceride (TG) cycle and De Novo Lipogenesis (DNL). Fatty acids which exist widely in organisms are components of cell membranes and play an indispensable role in cell signaling. In addition, FFAs can be taken up from circulating plasma by all mitochondria-containing cells, and they are metabolized by β-oxidation and the citric acid cycle to release large amounts of energy in the form of ATP. Abnormal fatty acid metabolism is associated with the occurrence and development of cardiovascular diseases, diabetes, fatty liver, hyperthyroidism, and other diseases.

MCE offers a unique collection of fatty acid compounds. Fatty Acids Compound Library is an important tool for the study of energy metabolism and drug development of metabolism-related diseases.

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N0468

Rebaudioside D 1 Publications Verification	Structural Classification other families Classification of Application Fields Terpenoids Metabolic Disease Diterpenoids Plants Disease Research Fields Sweeteners Source Classification Food Research	FXR Acetyl-CoA Carboxylase
Rebaudioside D is an orally active sweetener that targets and activates FXR, modulates Acetyl-CoA Carboxylase, and inhibits 3-hydroxy-3-methylglutaryl-CoA reductase. Rebaudioside D regulates bile acid homeostasis and lipid metabolism, reduces the synthesis rates of fatty acids and cholesterol, and exerts multiple effects including anti-adipogenesis, hepatoprotection, anti-steatosis, gut microbiota modulation, enhancement of secondary bile acid metabolism, anti-endotoxin activity, regulation of bile acid transport, and inhibition of bile acid efflux. Rebaudioside D also reduces body weight gain, visceral fat accumulation, hepatic triglyceride and cholesterol accumulation, hepatic lipid peroxidation, and decreases the circulating level of lipopolysaccharide-binding protein. Rebaudioside D additionally enhances the secondary bile acid metabolic pathway of intestinal bacteria, upregulates the gene expression of ileal organic solute transporter α, and downregulates the gene expression of hepatic bile salt export pump. Rebaudioside D does not affect glucose homeostasis, alter total caloric intake or fecal energy excretion, induce weight gain, exacerbate obesity, promote hepatic steatosis, impair brown adipose tissue function, nor change skeletal muscle metabolism-related proteins. Rebaudioside D can be used in diet-induced obesity and obesity-related research .

HY-N0686

Pseudoprotodioscin 1 Publications Verification	Structural Classification Classification of Application Fields Dioscorea nipponica Makino Metabolic Disease Plants Disease Research Fields Steroids Dioscoreaceae Source Classification	Fatty Acid Synthase (FASN) MicroRNA
Pseudoprotodioscin, a furostanoside, inhibits SREBP1/2 and microRNA 33a/b levels and reduces the gene expression regarding the synthesis of cholesterol and triglycerides .

HY-N14035

Garcinia cambogia extract	Structural Classification Natural Products Guttiferae Garcinia cambogia Desr. Plants Source Classification	FABP PPAR
Garcinia cambogia extract is an orally active anti-obesity agent . Garcinia cambogia extract upregulates the gene expression of aP2, SREBP1c, PPARγ2 and C/EBPα. Garcinia cambogia extract reduces the rate of body weight gain, visceral fat accumulation, lipid levels in blood and liver, as well as plasma insulin and leptin levels . Garcinia cambogia extract ameliorates high-fat diet-induced obesity .

HY-N0468R

Rebaudioside D (Standard)	Structural Classification other families Terpenoids Diterpenoids Plants Source Classification	Reference Standards Acetyl-CoA Carboxylase FXR
Rebaudioside D (Standard) is the analytical standard of Rebaudioside D. This product is intended for research and analytical applications. Rebaudioside D is an orally active sweetener that targets and activates FXR, modulates Acetyl-CoA Carboxylase, and inhibits 3-hydroxy-3-methylglutaryl-CoA reductase. Rebaudioside D regulates bile acid homeostasis and lipid metabolism, reduces the synthesis rates of fatty acids and cholesterol, and exerts multiple effects including anti-adipogenesis, hepatoprotection, anti-steatosis, gut microbiota modulation, enhancement of secondary bile acid metabolism, anti-endotoxin activity, regulation of bile acid transport, and inhibition of bile acid efflux. Rebaudioside D also reduces body weight gain, visceral fat accumulation, hepatic triglyceride and cholesterol accumulation, hepatic lipid peroxidation, and decreases the circulating level of lipopolysaccharide-binding protein. Rebaudioside D additionally enhances the secondary bile acid metabolic pathway of intestinal bacteria, upregulates the gene expression of ileal organic solute transporter α, and downregulates the gene expression of hepatic bile salt export pump. Rebaudioside D does not affect glucose homeostasis, alter total caloric intake or fecal energy excretion, induce weight gain, exacerbate obesity, promote hepatic steatosis, impair brown adipose tissue function, nor change skeletal muscle metabolism-related proteins. Rebaudioside D can be used in diet-induced obesity and obesity-related research .

HY-N9535

tert-OMe-byakangelicin	Classification of Application Fields Coumarins Metabolic Disease Phenylpropanoids Umbelliferae Helogyne apaloidea Nutt. Plants Disease Research Fields Source Classification	Others
tert-OMe-byakangelicin is a coumarin that can enhances the adrenaline-induced lipolytic effect and inhibits insulin-stimulated triglyceride synthesis from glucose in fat cells .

HY-N0686R

Pseudoprotodioscin (Standard)	Structural Classification Natural Products Dioscorea nipponica Makino Plants Dioscoreaceae Source Classification	Reference Standards Fatty Acid Synthase (FASN) MicroRNA
Pseudoprotodioscin (Standard) is the analytical standard of Pseudoprotodioscin. This product is intended for research and analytical applications. Pseudoprotodioscin, a furostanoside, inhibits SREBP1/2 and microRNA 33a/b levels and reduces the gene expression regarding the synthesis of cholesterol and triglycerides .

Cat. No.	Product Name	Chemical Structure

HY-W015600S

2-Acetamidophenol-d3
2-Acetamidophenol-d₃ (Orthocetamol-d₃) is the deuterium labeled 2-Acetamidophenol (HY-W015600). 2-Acetamidophenol (Orthocetamol) is a regulator that targets ferroptosis and glutathione metabolic pathways, is the ortho-regioisomer of Paracetamol (HY-66005). 2-Acetamidophenol has anti-atherosclerotic activity, and inhibiting total cholesterol (TC) and triglyceride (TG) in a zebrafish hyperlipidemia model with IC50s for 30 μM and 40 μM, respectively. 2-Acetamidophenol upregulates the expression of glutathione synthesis-related genes (such as GCLC, GCLM, GSS) and iron ion transport genes (such as FPN1, FTH), reduces the accumulation of intracellular reactive oxygen species (ROS) and ferrous ions (Fe2+), and enhances the activity of glutathione peroxidase GPX4, thereby inhibiting macrophage phagocytosis of oxidized low-density lipoprotein (ox-LDL) and foam cell formation .

2-Acetamidophenol-d3

2-Acetamidophenol-d₃ (Orthocetamol-d₃) is the deuterium labeled 2-Acetamidophenol (HY-W015600). 2-Acetamidophenol (Orthocetamol) is a regulator that targets ferroptosis and glutathione metabolic pathways, is the ortho-regioisomer of Paracetamol (HY-66005). 2-Acetamidophenol has anti-atherosclerotic activity, and inhibiting total cholesterol (TC) and triglyceride (TG) in a zebrafish hyperlipidemia model with IC50s for 30 μM and 40 μM, respectively. 2-Acetamidophenol upregulates the expression of glutathione synthesis-related genes (such as GCLC, GCLM, GSS) and iron ion transport genes (such as FPN1, FTH), reduces the accumulation of intracellular reactive oxygen species (ROS) and ferrous ions (Fe2+), and enhances the activity of glutathione peroxidase GPX4, thereby inhibiting macrophage phagocytosis of oxidized low-density lipoprotein (ox-LDL) and foam cell formation .

Cat. No.	Product Name		Classification

HY-153491

Olezarsen ISIS 678354; IONIS-APOCIII-LRx; AKCEA-APOCIII-LRx		Antisense Oligonucleotides
Olezarsen (ISIS 678354;IONIS-APOCIII-LRx) is a GalNAc-modified antisense oligonucleotide. Olezarsen binds to APOC3 mRNA and induces its degradation via ribonuclease H1-mediated sense strand cleavage, thereby reducing hepatic apolipoprotein C-III (apoC-III) synthesis. Olezarsen reduces plasma triglyceride, apolipoprotein B and non-high-density lipoprotein cholesterol levels. Olezarsen is applicable to research related to familial chylomicronemia syndrome, hypertriglyceridemia and atherosclerotic cardiovascular disease .

HY-153491A

Olezarsen sodium ISIS 678354 sodium; IONIS-APOCIII-LRx sodium; AKCEA-APOCIII-LRx sodium		Antisense Oligonucleotides
Olezarsen (ISIS 678354;IONIS-APOCIII-LRx) sodium is a GalNAc-modified antisense oligonucleotide. Olezarsen sodium binds to APOC3 mRNA and induces its degradation via ribonuclease H1-mediated sense strand cleavage, thereby reducing hepatic apolipoprotein C-III (apoC-III) synthesis. Olezarsen sodium reduces plasma triglyceride, apolipoprotein B and non-high-density lipoprotein cholesterol levels. Olezarsen sodium is applicable to research related to familial chylomicronemia syndrome, hypertriglyceridemia and atherosclerotic cardiovascular disease .

HY-153497A

Vupanorsen sodium IONIS ANGPT-L3Rx sodium; ISIS 703802 sodium		Antisense Oligonucleotides
Vupanorsen (sodium) is an N-acetyl galactosamine-conjugated antisense oligonucleotide that inhibits Angiopoietin-like 3 (ANGPTL3) protein synthesis. Vupanorsen (sodium) lowers triglycerides and atherogenic lipoproteins.

HY-153497

Vupanorsen IONIS ANGPT-L3Rx; ISIS 703802		Antisense Oligonucleotides
Vupanorsen is an N-acetyl galactosamine-conjugated antisense oligonucleotide that inhibits Angiopoietin-like 3 (ANGPTL3) protein synthesis. Vupanorsen lowers triglycerides and atherogenic lipoproteins.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

triglyceride synthesis

Inhibitors & Agonists

Screening Libraries

NaturalProducts

Isotope-Labeled Compounds

Oligonucleotides

Natural
Products